

Cristina Fhied

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1624434/publications.pdf>

Version: 2024-02-01

10
papers

82
citations

1684188

5
h-index

1720034

7
g-index

10
all docs

10
docs citations

10
times ranked

172
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. <i>International Journal of Cancer</i> , 2011, 129, 133-142.	5.1	28
2	Circulating Angiogenesis Biomarkers Are Associated With Disease Progression in Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1968-1975.	1.3	18
3	Development of a bead-based immunoassay to routinely measure vimentin autoantibodies in the clinical setting. <i>Journal of Immunological Methods</i> , 2014, 407, 9-14.	1.4	15
4	Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 727-734.e3.	0.8	12
5	Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. <i>Annals of Thoracic Surgery</i> , 2015, 100, 429-436.	1.3	6
6	Potential predictive value of hepatocyte growth factor (HGF) in advanced non-small cell lung cancer (NSCLC) treated with a platinum doublet and bevacizumab. <i>Journal of Clinical Oncology</i> , 2014, 32, e22000-e22000.	1.6	2
7	Differences in circulating angiogenic biomarkers as prognosticator for outcome in bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 11037-11037.	1.6	1
8	Panel of serum biomarkers to predict benefit from bevacizumab (BEV) in advanced NSCLC patients. <i>Journal of Clinical Oncology</i> , 2012, 30, e21069-e21069.	1.6	0
9	The prognostic significance of circulating angiogenesis biomarkers in stage I NSCLC. <i>Journal of Clinical Oncology</i> , 2015, 33, e13506-e13506.	1.6	0
10	Plasma biomarkers to help guide the management of patients with indeterminate findings during low-dose CT (LDCT) lung cancer screening. <i>Journal of Clinical Oncology</i> , 2015, 33, e22264-e22264.	1.6	0